New flu vaccine approved for European market

GlaxoSmithKline, a pharmaceutical company, recently announced approval to be the first to market its four-strain seasonal influenza vaccine, marketed as Influsplit Tetra and Fluarix Tetra, in Germany and the UK respectively.

This is the first time a four-strain influenza vaccine has gained approval in Europe. It is expected to be launched in time for the upcoming flu season, Zacks reports.

The vaccine helps protect adults and children over the age of 3 from influenza. This vaccine specifically protects against two influenza A virus subtypes and two influenza B virus types.

The vaccine gained approval from the U.S. Food and Drug Administration in December, after the FDA conducted studies Fluarix-US-005, FLU-056 and Fluarix-062 to test its public safety. GlaxoSmithKline is also currently seeking approval from the FDA for pandemic influenza vaccine candidate Q-Pan H5N1, according to Zacks.

GlaxoSmithKline is working to expand its market further into Australia, Switzerland and Taiwan. The company currently has a strong vaccine portfolio, including over five vaccinations against a range of viruses.